


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


Claim 1 (original): A fused pyrimidine derivative or a pharmaceutically acceptable salt thereof represented by Formula (I):



{wherein R¹ represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aromatic heterocyclic group; n represents an integer of 0 to 3; X¹ and X² may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aromatic heterocyclic group; and formula (II):




represents formula (III):



(III)

[wherein X--Y--Z represents $R^2C=CR^3-NR^4$ (wherein R^2 , R^3 and R^4 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aromatic heterocyclic group), $R^2C=N-NR^4$ (wherein R^2 and R^4 have the same meanings as defined above, respectively), $R^4N-CR^3=CR^2$ (wherein R^2 , R^3 and R^4 have the same meanings as defined above, respectively), or $R^4N-N=CR^2$ (wherein R^2 and R^4 have the same meanings as defined above, respectively)] or formula (IV):



(IV)

[wherein $Xa--Ya--Za$ represents $R^2HC-NR^3-CHR^4$ (wherein R^2 , R^3 and R^4 have the same meanings as defined above, respectively), R^2HC-NR^3-NH (wherein R^2 and R^3 have the same meanings as defined above, respectively), or $NH-NR^3-CHR^4$ (wherein R^3 and R^4 have the same meanings as defined above, respectively)]}.

Claim 2 (original): The fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein R^1 is substituted or unsubstituted lower alkyl.

Claim 3 (currently amended): The fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R^3 is substituted or unsubstituted aryl, or substituted or unsubstituted lower alkyl.

Claim 4 (currently amended): The fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to ~~any one of claims 1 to 3~~ claim 1, wherein X^1 is substituted or unsubstituted aralkyl and X^2 is a hydrogen atom.

Claim 5 (currently amended): A Pharmaceutical composition comprising the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to ~~any one of claims 1 to 4~~ claim 1 as an active ingredient.

Claim 6 (currently amended): A therapeutic agent for diabetes comprising the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to ~~any one of claims 1 to 4~~ claim 1 as an active ingredient.

Claim 7 (currently amended): A preventive and/or therapeutic agent for diabetic complications comprising the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to ~~any one of claims 1 to 4~~ claim 1 as an active ingredient.

Claim 8 (currently amended): A blood glucose-lowering agent comprising the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to ~~any one of claims 1 to 4~~ claim 1 as an active ingredient.

Claim 9 (currently amended): An insulin secretagogue comprising the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to ~~any one of claims 1 to 4~~ claim 1 as an active ingredient.

Claims 10-13 (canceled)

Claim 14 (currently amended): A method for treating diabetes, which comprises administering an effective amount of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to ~~any one of claims 1 to 4~~claim 1.

Claim 15 (currently amended): A method for preventing and/or treating diabetic complications, which comprises administering an effective amount of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to ~~any one of claims 1 to 4~~claim 1.

Claim 16 (currently amended): A method for lowering blood glucose levels, which comprises administering an effective amount of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to ~~any one of claims 1 to 4~~claim 1.

Claim 17 (currently amended): A method for stimulating secretion of insulin, which comprises administering an effective amount of the fused pyrimidine derivative or a pharmaceutically acceptable salt thereof according to ~~any one of claims 1 to 4~~claim 1.